Quinoline‐based thiazolyl‐hydrazones target cancer cells through autophagy inhibition
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Vladimir Ćurčić und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry, University of Belgrade, Belgrade, Serbia. Hauptthemen laut MEDLINE: Quinolines, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Ministry of Science, Technological Development and Innovation of the Republic of Serbia, AIRC IG 2020, CIBBS Germany's Excellence Strategy-EXC-2189.
Abstract (Originalsprache)
Heterocyclic pharmacophores such as thiazole and quinoline rings have a significant role in medicinal chemistry. They are considered privileged structures since they constitute several Food and Drug Administration (FDA)‐approved drugs for cancer treatment. Herein, we report the synthesis, in silico evaluation of the ADMET profiles, and in vitro investigation of the anticancer activity of a series of novel thiazolyl‐hydrazones based on the 8‐quinoline ( 1a–c ), 2‐quinoline ( 2a–c ), and 8‐hydroxy‐2‐quinolyl moiety ( 3a–c ). The panel of several human cancer cell lines and the nontumorigenic human embryonic kidney cell line HEK‐293 were used to evaluate the compound‐mediated in vitro anticancer activities, leading to [2‐(2‐(quinolyl‐8‐ol‐2‐ylmethylene)hydrazinyl)]‐4‐(4‐methoxyphenyl)‐1,3‐thiazole ( 3c ) as the most promising compound. The study revealed that 3c blocks the cell‐cycle progression of a human colon cancer cell line (HCT‐116) in the S phase and induces DNA double‐strand breaks. Also, our findings demonstrate that 3c accumulates in lysosomes, ultimately leading to the cell death of the hepatocellular carcinoma cell line (Hep‐G2) and HCT‐116 cells, by the mechanism of autophagy inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia.
- Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland.
- Division of Physical Chemistry, Institute Ruđer Bošković, Zagreb, Croatia.
- Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
- Institute of Chemistry, University of Tartu, Tartu, Estonia.
Förderung
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia
- AIRC IG 2020
- CIBBS Germany's Excellence Strategy-EXC-2189
- Estonian Research Council
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation): SFB 992
Zitieren
APA
Ćurčić, V., Olszewski, M., Maciejewska, N., Višnjevac, A., Srdić-Rajić, T., Dobričić, V., García-Sosa, A. T., Kokanov, S. B., Araškov, J. B., Silvestri, R., Schüle, R., Jung, M., Nikolić, M., & Filipović, N. R. (2024). Quinoline‐based thiazolyl‐hydrazones target cancer cells through autophagy inhibition. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300426
Vancouver
Ćurčić V, Olszewski M, Maciejewska N, Višnjevac A, Srdić-Rajić T, Dobričić V, et al. Quinoline‐based thiazolyl‐hydrazones target cancer cells through autophagy inhibition. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300426
BibTeX
@article{uri2024,
author = {Ćurčić, Vladimir and Olszewski, Mateusz and Maciejewska, Natalia and Višnjevac, Aleksandar and Srdić-Rajić, Tatjana and Dobričić, Vladimir and García-Sosa, Alfonso T and Kokanov, Sanja B and Araškov, Jovana B and Silvestri, Romano and Schüle, Roland and Jung, Manfred and Nikolić, Milan and Filipović, Nenad R},
title = {Quinoline‐based thiazolyl‐hydrazones target cancer cells through autophagy inhibition},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300426}
}
EUVIMED